Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L5YF
|
||||
| Former ID |
DIB010867
|
||||
| Drug Name |
ZD-4190
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Terminated | [1] | ||
| Company |
AstraZeneca plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H17BrClFN6O2
|
||||
| Canonical SMILES |
c12c(Nc3c(cc(cc3)Br)F)ncnc1cc(c(c2)OC)OCCn1nncc1.Cl
|
||||
| CAS Number |
CAS 257938-36-6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | VEGF receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009540) | ||||
| REF 2 | ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.